参考文献/References:
[1]Mok J,Kang H,Hwang SH,et al.Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea[J].J Antimicrob Chemother,2018,73(2):503-508.[2]World Health Organization.WHO consolidated guidelines on drug-resistant tuberculosis treatment[M].Geneva:World Health Organization,2019.[3]World Health Organization.Global tuberculosis report 2019[M].Geneva:World Health Organization,2019.[4]Pontali E,Centis R,D’Ambrosio L,et al.Recent evidence on delamanid use for rifampicin-resistant tuberculosis[J].J Thorac Dis,2019,11(Suppl 3):S457-S460.[5]Chen XH,Hashizume H,Tomishige T,et al.Delamanid kills dormant Mycobacteria in vitro and in a guinea pig model of tuberculosis[J].Antimicrob Agents Chemother,2017,61(6):e02402-e02416.[6]Shibata M,Shimokawa Y,Sasahara K,et al.Absorption, distribution and excretion of the anti-tuberculosis drug delamanid in rats: extensive tissue distribution suggests potential therapeutic value for extrapulmonary tuberculosis[J].Biopharm Drug Dispos,2017,38(4):301-312.[7]Liu Y,Matsumoto M,Ishida H,et al.Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)[J].Tuberculosis (Edinb),2018,111:20-30.[8]中华医学会结核病学分会.中国耐多药和利福平耐药结核病治疗专家共识(2019年版)[J].中华结核和呼吸杂志,2019,42(10):733-749.[9]Polsfuss S,Hofmann-Thiel S,Merker M,et al.Emergence of low-level delamanid and bedaquiline resistance during extremely drug-resistant tuberculosis treatment[J].Clin Infect Dis,2019,69(7):1229-1231.[10]Chang KC,Leung ECC,Law WS,et al.Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong[J].Eur Respir J,2018,51(6):1800159.[11]Kempker RR,Mikiashvili L,Zhao Y,et al.Clinical outcomes among patients with drug-resistant tuberculosis receiving bedaquiline or delamanid containing regimens[J].Clin Infect Dis,2019,12:ciz1107.[12]中华医学会结核病学分会.德拉马尼临床应用专家共识[J].中华结核和呼吸杂志,2022,45(9):872-880.[13]BocheneK T,Abilova V,Alkan A,et al.Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian countries[J].Front Pharmacol,2017,8:942.[14]Groote-Bidlingmaier F,Patientia R,Sanchez E,et al.Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial[J].Lancet Respir Med,2019,7(3):249-259.[15]Mohr E,Hughes J,Reuter A,et al.Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa[J].Eur Respir J,2018,51(6):1-11.[16]Lee M,Mok J,Kim DK,et al.Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (treatment shortening of MDR-TB using existing and new drugs, MDR-END): study protocol for a phase Ⅱ/Ⅲ,multicenter, randomized, open-label clinical trial[J].Trials,2019,20(1):57.[17]Kim CT,Kim TO,Shin HJ,et al.Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea[J].Eur Respir J,2018,51(3):1702467.[18]Sarin R,Vohra V,Singla N,et al.Early efficacy and safety of bedaquiline and delamanid given together in a〝 Salvage Regimen" for treatment of drug-resistant tuberculosis[J].Indian J Tuberc,2019,66(1):184-188.[19]Ferlazzo G,Mohr E,Laxmeshwar C,et al.Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study[J].Lancet Infect Dis,2018,18(5):536-544.[20]Mohr E,Ferlazzo G,Hewison C,et al.Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis[J].Lancet Infect Dis,2019,19(5):470.